NEW YORK (GenomeWeb) – Veracyte today said that it has signed a partnership with Fleury Medicine and Health to make its Afirma Gene Expression Classifier for thyroid cancer diagnosis available to patients in Brazil.

Fleury will exclusively offer the Afirma GEC through its diagnostics centers across Brazil. The genomic test will be offered when patients' thyroid nodule fine needle aspiration results are indeterminate following cytopathology review.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.